search
Back to results

Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer (CheckMate331)

Primary Purpose

Lung Cancer

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Nivolumab
Topotecan
Amrubicin
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically or cytologically confirmed small cell lung cancer (SCLC)
  • Subjects with either limited or extensive disease stage at the initial diagnosis
  • Must have recurrence or progression after platinum-based first-line chemotherapy or chemoradiation therapy for the treatment of limited or extensive disease stage SCLC
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

  • Untreated or symptomatic central nervous system (CNS) metastases
  • Prior therapy with anti-PD-1, anti-PDL1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody
  • Inadequate hematologic or hepatic function

Sites / Locations

  • Local Institution - 0065
  • Local Institution - 0024
  • Local Institution - 0018
  • Local Institution - 0056
  • Local Institution - 0088
  • Local Institution - 0173
  • Local Institution - 0001
  • Local Institution - 0090
  • Local Institution - 0002
  • Local Institution - 0057
  • Local Institution - 0053
  • Local Institution - 0089
  • Local Institution - 0009
  • Local Institution - 0070
  • Local Institution - 0102
  • Local Institution - 0030
  • Local Institution - 0031
  • Local Institution - 0103
  • Local Institution - 0028
  • Local Institution - 0027
  • Local Institution - 0085
  • Local Institution - 0084
  • Local Institution - 0086
  • Local Institution - 0013
  • Local Institution - 0012
  • Local Institution - 0011
  • Local Institution - 0010
  • Local Institution - 0095
  • Local Institution - 0094
  • Local Institution - 0093
  • Local Institution - 0099
  • Local Institution - 0025
  • Local Institution - 0200
  • Local Institution - 0199
  • Local Institution - 0188
  • Local Institution - 0190
  • Local Institution - 0197
  • Local Institution - 0189
  • Local Institution - 0194
  • Local Institution - 0187
  • Local Institution - 0186
  • Local Institution - 0181
  • Local Institution - 0185
  • Local Institution - 0202
  • Local Institution - 0183
  • Local Institution - 0201
  • Local Institution - 0198
  • Local Institution - 0182
  • Local Institution - 0192
  • Local Institution - 0069
  • Local Institution - 0067
  • Local Institution - 0068
  • Local Institution - 0066
  • Local Institution - 0106
  • Local Institution - 0098
  • Local Institution - 0100
  • Local Institution - 0134
  • Local Institution - 0116
  • Local Institution - 0118
  • Local Institution - 0131
  • Local Institution - 0132
  • Local Institution - 0117
  • Local Institution - 0061
  • Local Institution - 0055
  • Local Institution - 0047
  • Local Institution - 0071
  • Local Institution - 0060
  • Local Institution - 0019
  • Local Institution - 0021
  • Local Institution - 0058
  • Local Institution - 0059
  • Local Institution - 0020
  • Local Institution - 0046
  • Local Institution - 0023
  • Local Institution - 0022
  • Local Institution - 0054
  • Local Institution - 0064
  • Local Institution - 0063
  • Local Institution - 0062
  • Local Institution - 0097
  • Local Institution - 0112
  • Local Institution - 0110
  • Local Institution - 0150
  • Local Institution - 0139
  • Local Institution - 0138
  • Local Institution - 0136
  • Local Institution - 0166
  • Local Institution - 0081
  • Local Institution - 0073
  • Local Institution - 0108
  • Local Institution - 0077
  • Local Institution - 0078
  • Local Institution - 0080
  • Local Institution - 0107
  • Local Institution - 0079
  • Local Institution - 0159
  • Local Institution - 0169
  • Local Institution - 0196
  • Local Institution - 0155
  • Local Institution - 0153
  • Local Institution - 0168
  • Local Institution - 0163
  • Local Institution - 0164
  • Local Institution - 0161
  • Local Institution - 0171
  • Local Institution - 0175
  • Local Institution - 0151
  • Local Institution - 0165
  • Local Institution - 0160
  • Local Institution - 0162
  • Local Institution - 0176
  • Local Institution - 0170
  • Local Institution - 0174
  • Local Institution - 0152
  • Local Institution - 0154
  • Local Institution - 0145
  • Local Institution - 0146
  • Local Institution - 0147
  • Local Institution - 0148
  • Local Institution - 0096
  • Local Institution - 0072
  • Local Institution - 0044
  • Local Institution - 0041
  • Local Institution - 0032
  • Local Institution - 0033
  • Local Institution - 0042
  • Local Institution - 0035
  • Local Institution - 0135
  • Local Institution - 0114
  • Local Institution - 0113
  • Local Institution - 0149
  • Local Institution - 0122
  • Local Institution - 0121
  • Local Institution - 0126
  • Local Institution - 0119
  • Local Institution - 0006
  • Local Institution - 0005
  • Local Institution - 0004
  • Local Institution - 0003
  • Local Institution - 0008
  • Local Institution - 0007
  • Local Institution - 0104
  • Local Institution - 0133
  • Local Institution - 0109
  • Local Institution - 0156
  • Local Institution - 0143
  • Local Institution - 0157
  • Local Institution - 0082
  • Local Institution - 0083
  • Local Institution - 0124
  • Local Institution - 0123

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Arm A Nivolumab

Arm B Chemotherapy Topotecan

Arm B Chemotherapy Amrubicin

Arm Description

Nivolumab intravenous infusion as specified

Topotecan as specified

Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)

Outcomes

Primary Outcome Measures

Overall Survival (OS)
The time from randomization to the date of death, data was based on Kaplan-Meier Estimates. A participant who has not died will be censored at last known date alive.

Secondary Outcome Measures

Progression Free Survival (PFS)
PFS is defined as the time from randomization to the date of the first documented tumor progression based on investigator assessment (per RECIST 1.1), or death due to any cause. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die will be censored on the date they were randomized. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Progressive disease (PD)= At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The sum must demonstrate an absolute increase of at least 5 mm.
Objective Response Rate (ORR)
ORR is defined as the percentage of randomized participants whose best overall response (BOR) from baseline is either a complete response (CR) or partial response (PR) based on investigator assessment per RECIST 1.1 criteria. For participants without documented progression or subsequent anti-cancer therapy, all available response designations will contribute to the BOR determination. For participants who continue nivolumab beyond progression, the BOR should be determined based on tumor assessments before initial RECIST 1.1 defined progression. CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)= At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The sum must demonstrate an absolute increase of at least 5 mm.

Full Information

First Posted
June 23, 2015
Last Updated
July 19, 2023
Sponsor
Bristol-Myers Squibb
Collaborators
Ono Pharmaceutical Co. Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT02481830
Brief Title
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
Acronym
CheckMate331
Official Title
An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
September 14, 2015 (Actual)
Primary Completion Date
August 17, 2018 (Actual)
Study Completion Date
August 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb
Collaborators
Ono Pharmaceutical Co. Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
569 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm A Nivolumab
Arm Type
Experimental
Arm Description
Nivolumab intravenous infusion as specified
Arm Title
Arm B Chemotherapy Topotecan
Arm Type
Active Comparator
Arm Description
Topotecan as specified
Arm Title
Arm B Chemotherapy Amrubicin
Arm Type
Active Comparator
Arm Description
Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)
Intervention Type
Drug
Intervention Name(s)
Nivolumab
Intervention Type
Drug
Intervention Name(s)
Topotecan
Intervention Type
Drug
Intervention Name(s)
Amrubicin
Primary Outcome Measure Information:
Title
Overall Survival (OS)
Description
The time from randomization to the date of death, data was based on Kaplan-Meier Estimates. A participant who has not died will be censored at last known date alive.
Time Frame
OS was followed continuously while participants were on the study drug and every 3 months, minimum follow up for overall survival was 15.8 months
Secondary Outcome Measure Information:
Title
Progression Free Survival (PFS)
Description
PFS is defined as the time from randomization to the date of the first documented tumor progression based on investigator assessment (per RECIST 1.1), or death due to any cause. Participants who die without a reported prior progression will be considered to have progressed on the date of their death. Participants who did not progress or die will be censored on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die will be censored on the date they were randomized. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Progressive disease (PD)= At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The sum must demonstrate an absolute increase of at least 5 mm.
Time Frame
From randomization to the date of first documented tumor progression, or death due to any cause. Tumor response assessed every 6 weeks from first dose until week 30, and every 12 weeks (Up to approximately 80 months)
Title
Objective Response Rate (ORR)
Description
ORR is defined as the percentage of randomized participants whose best overall response (BOR) from baseline is either a complete response (CR) or partial response (PR) based on investigator assessment per RECIST 1.1 criteria. For participants without documented progression or subsequent anti-cancer therapy, all available response designations will contribute to the BOR determination. For participants who continue nivolumab beyond progression, the BOR should be determined based on tumor assessments before initial RECIST 1.1 defined progression. CR= Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD)= At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The sum must demonstrate an absolute increase of at least 5 mm.
Time Frame
From randomization to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to approximately 80 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed small cell lung cancer (SCLC) Subjects with either limited or extensive disease stage at the initial diagnosis Must have recurrence or progression after platinum-based first-line chemotherapy or chemoradiation therapy for the treatment of limited or extensive disease stage SCLC Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: Untreated or symptomatic central nervous system (CNS) metastases Prior therapy with anti-PD-1, anti-PDL1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody Inadequate hematologic or hepatic function
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution - 0065
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Facility Name
Local Institution - 0024
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Local Institution - 0018
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Local Institution - 0056
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Local Institution - 0088
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68506
Country
United States
Facility Name
Local Institution - 0173
City
Johnson City
State/Province
New York
ZIP/Postal Code
13790
Country
United States
Facility Name
Local Institution - 0001
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Local Institution - 0090
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Local Institution - 0002
City
Bethlehem
State/Province
Pennsylvania
ZIP/Postal Code
18015
Country
United States
Facility Name
Local Institution - 0057
City
Lancaster
State/Province
Pennsylvania
ZIP/Postal Code
17604
Country
United States
Facility Name
Local Institution - 0053
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111-2412
Country
United States
Facility Name
Local Institution - 0089
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Local Institution - 0009
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Facility Name
Local Institution - 0070
City
Kennewick
State/Province
Washington
ZIP/Postal Code
99336
Country
United States
Facility Name
Local Institution - 0102
City
Waratah
State/Province
New South Wales
ZIP/Postal Code
2298
Country
Australia
Facility Name
Local Institution - 0030
City
Brisbane
State/Province
Queensland
ZIP/Postal Code
4032
Country
Australia
Facility Name
Local Institution - 0031
City
Elizabeth Vale
State/Province
South Australia
ZIP/Postal Code
5112
Country
Australia
Facility Name
Local Institution - 0103
City
Kurralta Park
State/Province
South Australia
ZIP/Postal Code
5037
Country
Australia
Facility Name
Local Institution - 0028
City
Perth
State/Province
Western Australia
ZIP/Postal Code
6150
Country
Australia
Facility Name
Local Institution - 0027
City
Murdoch
ZIP/Postal Code
6150
Country
Australia
Facility Name
Local Institution - 0085
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Local Institution - 0084
City
Wels
ZIP/Postal Code
4600
Country
Austria
Facility Name
Local Institution - 0086
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
Local Institution - 0013
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Local Institution - 0012
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Facility Name
Local Institution - 0011
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Local Institution - 0010
City
Yvoir
ZIP/Postal Code
5530
Country
Belgium
Facility Name
Local Institution - 0095
City
Ijui
State/Province
RIO Grande DO SUL
ZIP/Postal Code
98700-000
Country
Brazil
Facility Name
Local Institution - 0094
City
Porto Alegre
State/Province
Rio Grande Do Sul
ZIP/Postal Code
90610-000
Country
Brazil
Facility Name
Local Institution - 0093
City
Barretos
State/Province
Sao Paulo
ZIP/Postal Code
14784-400
Country
Brazil
Facility Name
Local Institution - 0099
City
Sao Paulo
ZIP/Postal Code
01321-001
Country
Brazil
Facility Name
Local Institution - 0025
City
Recoleta
State/Province
Santiago De Chile
ZIP/Postal Code
0
Country
Chile
Facility Name
Local Institution - 0200
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100001
Country
China
Facility Name
Local Institution - 0199
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100021
Country
China
Facility Name
Local Institution - 0188
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100032
Country
China
Facility Name
Local Institution - 0190
City
Beijing
State/Province
Beijing
ZIP/Postal Code
101149
Country
China
Facility Name
Local Institution - 0197
City
Guanzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
Facility Name
Local Institution - 0189
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450008
Country
China
Facility Name
Local Institution - 0194
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210000
Country
China
Facility Name
Local Institution - 0187
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130012
Country
China
Facility Name
Local Institution - 0186
City
Xian
State/Province
Shaanxi
ZIP/Postal Code
710038
Country
China
Facility Name
Local Institution - 0181
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China
Facility Name
Local Institution - 0185
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Name
Local Institution - 0202
City
Urumqi
State/Province
Xinjiang
ZIP/Postal Code
830011
Country
China
Facility Name
Local Institution - 0183
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310022
Country
China
Facility Name
Local Institution - 0201
City
Beijing
ZIP/Postal Code
100071
Country
China
Facility Name
Local Institution - 0198
City
Guangzhou
ZIP/Postal Code
0
Country
China
Facility Name
Local Institution - 0182
City
Hangzhou
ZIP/Postal Code
310016
Country
China
Facility Name
Local Institution - 0192
City
Shanghai
ZIP/Postal Code
200030
Country
China
Facility Name
Local Institution - 0069
City
Brno
ZIP/Postal Code
625 00
Country
Czechia
Facility Name
Local Institution - 0067
City
Brno
ZIP/Postal Code
656 53
Country
Czechia
Facility Name
Local Institution - 0068
City
Olomouc
ZIP/Postal Code
779 00
Country
Czechia
Facility Name
Local Institution - 0066
City
Praha 4
ZIP/Postal Code
14059
Country
Czechia
Facility Name
Local Institution - 0106
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Facility Name
Local Institution - 0098
City
Herlev
ZIP/Postal Code
2730
Country
Denmark
Facility Name
Local Institution - 0100
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Facility Name
Local Institution - 0134
City
Brest
ZIP/Postal Code
29200
Country
France
Facility Name
Local Institution - 0116
City
Lille Cedex
ZIP/Postal Code
59037
Country
France
Facility Name
Local Institution - 0118
City
Paris Cedex 14
ZIP/Postal Code
75014
Country
France
Facility Name
Local Institution - 0131
City
Pringy Cedex
ZIP/Postal Code
74374
Country
France
Facility Name
Local Institution - 0132
City
Reims
ZIP/Postal Code
51100
Country
France
Facility Name
Local Institution - 0117
City
Toulon Cedex
ZIP/Postal Code
83056
Country
France
Facility Name
Local Institution - 0061
City
Bamberg
ZIP/Postal Code
96049
Country
Germany
Facility Name
Local Institution - 0055
City
Berlin
ZIP/Postal Code
13125
Country
Germany
Facility Name
Local Institution - 0047
City
Essen
ZIP/Postal Code
45122
Country
Germany
Facility Name
Local Institution - 0071
City
Frankfurt am Main
ZIP/Postal Code
60590
Country
Germany
Facility Name
Local Institution - 0060
City
Gera
ZIP/Postal Code
07548
Country
Germany
Facility Name
Local Institution - 0019
City
Gerlingen
ZIP/Postal Code
70839
Country
Germany
Facility Name
Local Institution - 0021
City
Grosshansdorf
ZIP/Postal Code
22927
Country
Germany
Facility Name
Local Institution - 0058
City
Halle (saale)
ZIP/Postal Code
06120
Country
Germany
Facility Name
Local Institution - 0059
City
Hamburg
ZIP/Postal Code
21075
Country
Germany
Facility Name
Local Institution - 0020
City
Heidelberg
ZIP/Postal Code
69126
Country
Germany
Facility Name
Local Institution - 0046
City
Immenstadt
ZIP/Postal Code
87509
Country
Germany
Facility Name
Local Institution - 0023
City
Koeln
ZIP/Postal Code
50937
Country
Germany
Facility Name
Local Institution - 0022
City
Muenchen
ZIP/Postal Code
81925
Country
Germany
Facility Name
Local Institution - 0054
City
Oberhausen
ZIP/Postal Code
46145
Country
Germany
Facility Name
Local Institution - 0064
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
Facility Name
Local Institution - 0063
City
Heraklion
State/Province
Creta
ZIP/Postal Code
71110
Country
Greece
Facility Name
Local Institution - 0062
City
Athens
ZIP/Postal Code
11527
Country
Greece
Facility Name
Local Institution - 0097
City
Thessaloniki
ZIP/Postal Code
56429
Country
Greece
Facility Name
Local Institution - 0112
City
Budapest
ZIP/Postal Code
1083
Country
Hungary
Facility Name
Local Institution - 0110
City
Budapest
ZIP/Postal Code
1121
Country
Hungary
Facility Name
Local Institution - 0150
City
Budapest
ZIP/Postal Code
1121
Country
Hungary
Facility Name
Local Institution - 0139
City
Beer Sheva
ZIP/Postal Code
84101
Country
Israel
Facility Name
Local Institution - 0138
City
Kfar Saba
ZIP/Postal Code
0
Country
Israel
Facility Name
Local Institution - 0136
City
Ramat -Gan
ZIP/Postal Code
52621
Country
Israel
Facility Name
Local Institution - 0166
City
Safed
ZIP/Postal Code
13100
Country
Israel
Facility Name
Local Institution - 0081
City
Bologna
ZIP/Postal Code
40139
Country
Italy
Facility Name
Local Institution - 0073
City
Livorno
ZIP/Postal Code
57100
Country
Italy
Facility Name
Local Institution - 0108
City
Lucca
ZIP/Postal Code
55100
Country
Italy
Facility Name
Local Institution - 0077
City
Meldola
ZIP/Postal Code
47014
Country
Italy
Facility Name
Local Institution - 0078
City
Milano
ZIP/Postal Code
20133
Country
Italy
Facility Name
Local Institution - 0080
City
Monza
ZIP/Postal Code
20052
Country
Italy
Facility Name
Local Institution - 0107
City
Rimini
ZIP/Postal Code
47923
Country
Italy
Facility Name
Local Institution - 0079
City
Roma
ZIP/Postal Code
00189
Country
Italy
Facility Name
Local Institution - 0159
City
Nagoya-shi
State/Province
Aichi
ZIP/Postal Code
4648681
Country
Japan
Facility Name
Local Institution - 0169
City
Nagoya
State/Province
Aichi
ZIP/Postal Code
460-0001
Country
Japan
Facility Name
Local Institution - 0196
City
Kashiwa
State/Province
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Facility Name
Local Institution - 0155
City
Matsuyama
State/Province
Ehime
ZIP/Postal Code
7910280
Country
Japan
Facility Name
Local Institution - 0153
City
Fukuoka-shi
State/Province
Fukuoka
ZIP/Postal Code
811-1395
Country
Japan
Facility Name
Local Institution - 0168
City
Akashi-shi
State/Province
Hyogo
ZIP/Postal Code
6738558
Country
Japan
Facility Name
Local Institution - 0163
City
Kobe
State/Province
Hyogo
ZIP/Postal Code
6500047
Country
Japan
Facility Name
Local Institution - 0164
City
Natori-shi
State/Province
Miyagi
ZIP/Postal Code
9811293
Country
Japan
Facility Name
Local Institution - 0161
City
Niigata-shi
State/Province
Niigata
ZIP/Postal Code
951-8566
Country
Japan
Facility Name
Local Institution - 0171
City
Habikino-shi
State/Province
Osaka
ZIP/Postal Code
5838588
Country
Japan
Facility Name
Local Institution - 0175
City
Hirakata-shi
State/Province
Osaka
ZIP/Postal Code
5731191
Country
Japan
Facility Name
Local Institution - 0151
City
Osaka-sayama
State/Province
Osaka
ZIP/Postal Code
589-8511
Country
Japan
Facility Name
Local Institution - 0165
City
Osaka-shi
State/Province
Osaka
ZIP/Postal Code
5340021
Country
Japan
Facility Name
Local Institution - 0160
City
Sakai
State/Province
Osaka
ZIP/Postal Code
591-8555
Country
Japan
Facility Name
Local Institution - 0162
City
Kitaadachi-gun
State/Province
Saitama
ZIP/Postal Code
362-0806
Country
Japan
Facility Name
Local Institution - 0176
City
Bunkyo-ku
State/Province
Tokyo
ZIP/Postal Code
1138431
Country
Japan
Facility Name
Local Institution - 0170
City
Chuo-ku
State/Province
Tokyo
ZIP/Postal Code
1040045
Country
Japan
Facility Name
Local Institution - 0174
City
Chuo-ku
State/Province
Tokyo
ZIP/Postal Code
5418567
Country
Japan
Facility Name
Local Institution - 0152
City
Wakayama-Shi
State/Province
Wakayama
ZIP/Postal Code
641-8510
Country
Japan
Facility Name
Local Institution - 0154
City
Tokyo
ZIP/Postal Code
135-8550
Country
Japan
Facility Name
Local Institution - 0145
City
Suwon
State/Province
Gyeonggi-do
ZIP/Postal Code
16247
Country
Korea, Republic of
Facility Name
Local Institution - 0146
City
Cheongju-si
ZIP/Postal Code
28644
Country
Korea, Republic of
Facility Name
Local Institution - 0147
City
Seoul
ZIP/Postal Code
02841
Country
Korea, Republic of
Facility Name
Local Institution - 0148
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Local Institution - 0096
City
Bergen
ZIP/Postal Code
5021
Country
Norway
Facility Name
Local Institution - 0072
City
Oslo
ZIP/Postal Code
0424
Country
Norway
Facility Name
Local Institution - 0044
City
Elblag
ZIP/Postal Code
82-300
Country
Poland
Facility Name
Local Institution - 0041
City
Gdansk
ZIP/Postal Code
80-214
Country
Poland
Facility Name
Local Institution - 0032
City
Krakow
ZIP/Postal Code
31-202
Country
Poland
Facility Name
Local Institution - 0033
City
Lodz
ZIP/Postal Code
93-513
Country
Poland
Facility Name
Local Institution - 0042
City
Poznan
ZIP/Postal Code
60-569
Country
Poland
Facility Name
Local Institution - 0035
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Facility Name
Local Institution - 0135
City
Bucharest
ZIP/Postal Code
020122
Country
Romania
Facility Name
Local Institution - 0114
City
Craiova
ZIP/Postal Code
200347
Country
Romania
Facility Name
Local Institution - 0113
City
Romania
ZIP/Postal Code
400015
Country
Romania
Facility Name
Local Institution - 0149
City
Timisoara, Timis
ZIP/Postal Code
300239
Country
Romania
Facility Name
Local Institution - 0122
City
Moscow
ZIP/Postal Code
115478
Country
Russian Federation
Facility Name
Local Institution - 0121
City
Ryazan
ZIP/Postal Code
390011
Country
Russian Federation
Facility Name
Local Institution - 0126
City
Saint-Petersburg
ZIP/Postal Code
197758
Country
Russian Federation
Facility Name
Local Institution - 0119
City
St. Petersburg
ZIP/Postal Code
194291
Country
Russian Federation
Facility Name
Local Institution - 0006
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Facility Name
Local Institution - 0005
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Local Institution - 0004
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Local Institution - 0003
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Local Institution - 0008
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Facility Name
Local Institution - 0007
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Local Institution - 0104
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Facility Name
Local Institution - 0133
City
Lausanne
ZIP/Postal Code
1011
Country
Switzerland
Facility Name
Local Institution - 0109
City
Winterthur
ZIP/Postal Code
8401
Country
Switzerland
Facility Name
Local Institution - 0156
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland
Facility Name
Local Institution - 0143
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
Facility Name
Local Institution - 0157
City
London
State/Province
Greater London
ZIP/Postal Code
SW3 6JJ
Country
United Kingdom
Facility Name
Local Institution - 0082
City
Manchester
State/Province
Greater Manchester
ZIP/Postal Code
M20 4XB
Country
United Kingdom
Facility Name
Local Institution - 0083
City
Maidstone
State/Province
Kent
ZIP/Postal Code
ME16 9QQ
Country
United Kingdom
Facility Name
Local Institution - 0124
City
Sutton
State/Province
Surrey
ZIP/Postal Code
SM2 5PT
Country
United Kingdom
Facility Name
Local Institution - 0123
City
Southampton
ZIP/Postal Code
SO16 6YD
Country
United Kingdom

12. IPD Sharing Statement

Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
http://www.BMSStudyConnect.com
Description
BMS Clinical Trial Patient Recruiting

Learn more about this trial

Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer

We'll reach out to this number within 24 hrs